Trial
NCT00994214
Study to Assess the Efficacy and Safety of Repeated Administration of BIM 23A760 in Patients With Acromegaly
Phase IITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Ipsen
Collaborators
—
Condition
Acromegaly
Intervention
BIM 23A760
Why stopped
Preliminary data from this study does not support expected inhibition of GH and IGF-1
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2019-11-22